Your browser doesn't support javascript.
loading
Duration of Effectiveness Evaluation of Additional Risk Minimisation Measures for Centrally Authorised Medicinal Products in the EU Between 2012 and 2021.
Essink, Sharon C M; Zomerdijk, Inge M; Straus, Sabine M J M; Gardarsdottir, Helga; De Bruin, Marie L.
Affiliation
  • Essink SCM; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Zomerdijk IM; Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands.
  • Straus SMJM; Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands.
  • Gardarsdottir H; Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands.
  • De Bruin ML; Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands.
Drug Saf ; 46(10): 1007-1020, 2023 10.
Article in En | MEDLINE | ID: mdl-37658281
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Risk Management / Pharmacovigilance Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Risk Management / Pharmacovigilance Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Year: 2023 Type: Article